

Review Article

Severe Spectrums of SARS-CoV-2 Omicron Variant Infected Pediatric Cases

Jianguo Zhou¹, Guoping Lu² and Wenhao Zhou^{1,3*}

¹Department of Neonatology, Children's Hospital of Fudan University, Shanghai, China

²Pediatric Intensive Care Unit, Children's Hospital of Fudan University, Shanghai, China

³Molecular Medical Center, Children's Hospital of Fudan University, Shanghai, China, Shanghai Key Laboratory of Birth Defects, Shanghai, China

*Corresponding author: Wenhao Zhou, Molecular Medical Center, Children's Hospital of Fudan University, Shanghai, China, Shanghai Key Laboratory of Birth Defects, Shanghai, China

Received: May 31, 2022; Accepted: June 16, 2022;

Published: June 23, 2022

Abstract

Background: SARS-CoV-2 Omicron variant with so far the highest transmissible capability increases the risk of re-infection and vaccine breakthrough infections. Detection of what are the severe spectrums of SARS-CoV-2 Omicron variant-infected pediatric cases was essential in guiding clinical and public health strategies.

Data Sources: Original research articles and literature reviews were collected from databases, mainly PubMed. Relevant articles about severe COVID-19 infected pediatric cases and Omicron variant were included.

Results: Omicron infected pediatric cases were less severe than previous variant-infected cases, however, because of significantly increased cases, infants and children were hospitalized at a higher number. The severe spectrums of Omicron infected pediatric cases were slightly different from those in the pre-Omicron period. Seizure and croup were two major severe spectrums of SARS-CoV-2 Omicron variant-infected pediatric cases, while MIS-C was less frequent. Even though vaccine breakthrough infection was common, vaccination is effective in preventing hospitalization and critical cases.

Conclusions: SARS-CoV-2 Omicron variant-infected pediatric cases shared slightly different severe spectrums with previous variants. Vaccination is strongly recommended for eligible children for preventing hospitalization and critical Covid-19 cases.

Keywords: SARS-CoV-2; Omicron Variant; Pediatric Cases; Seizure; Croup

Introduction

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in December 2019 and rapidly spread globally. While the relative number of infected children was small (< 2% of reported cases) during the early stages of the pandemic [1-3], the true incidence of COVID-19 pediatric infections at that time may have been underestimated due to the high percentage of asymptomatic children and low testing rate [4]. As the pandemic progress, the relative proportion of pediatric cases has increased. Omicron variant, containing 32 mutations of the spike protein, emerged in late 2021 [5], and is characterized by higher transmissibility and immune evasion [6]. Pediatric cases have significantly increased.

The manifestation of severe pediatric COVID-19 cases presents in a similar clinical spectrum as in adults. Children may present with respiratory failure, myocarditis, shock, acute renal failure, coagulopathy, neurological involvement (encephalopathy, stroke, cerebral edema, Guillain-Barré syndrome), and multi-system organ failure [7,8]. However, other symptoms, such as seizure and croup, were typically high in SARS-CoV-2 Omicron variant infected pediatric cases.

Characteristics of SARS-CoV-2 Omicron Variant

Firstly, Omicron is a highly transmissible variant with reporting

doubling times of 3.38 d (95% CI 3.18–3.61 d) and 2–2.5 d, respectively [9,10] with the basic reproduction number (R_0) above 3. Researchers from Hong Kong have reported a 10 times faster growth of Omicron in bronchi as compared to delta (accounting for rapid spread) [11]. This property is accounting for its rapid spread and displacement of the previous variant, delta.

Secondly, the SARS-CoV-2 Omicron variant may increase the risk of re-infection and vaccine breakthrough infections as it possesses key mutations in the spike protein that affect neutralizing antibody response. Studies before the emergence of omicron showed a 0.1%–1% risk of re-infection and prior infection with SARS-CoV-2 to give more than 80% protection against reinfection [12]. Linear data analysis from South Africa showed that re-infection rates went up significantly during the omicron wave, but not during the beta and delta waves; the hazard ratio for re-infection vs. primary infection between 1st and 27th November was 2.39, compared to the first wave [13]. While a previous infection gave 80% protection against delta, it only gave 19% protection against omicron [10].

Thirdly, Omicron demonstrates a greater breakthrough against vaccine-induced immunity as compared to the delta. In vitro studies show that the neutralizing antibody titers induced by BNT162b2 against omicron were 44-fold lower and that by AZD1222 were 36-fold lower [14,15]. Similarly, neutralizing antibody titer against omicron was significantly lower in other vaccines [16]. The vaccine

efficacy against delta with 2 doses of AZD1222 was 44%, it was 5% with omicron, while, for the BNT162b2, the figures were 70% and 19%, respectively [17]. A study from South Africa showed that 2 doses of BNT162b2 were 70% protective against hospitalization during the omicron surge as compared to 93% before the omicron surge [18].

Overall Epidemiology of Covid-19 Infected Children

There is evidence-based consensus on the lower severity of COVID-19 in children and adolescents: the lower maturity of the immune system in Children leads to a less pro-inflammatory response that is associated with much of the morbidity and mortality observed in COVID-19 [19,20], lower expression of the ACE2 receptor in children, to which SARS-CoV-2 binds [20,21], and lower prevalence of co morbidities and risk factors associated with worse outcomes (diabetes, hypertension, etc.) in pediatric age 22-25. In children aged 0-5 years, the overall risks of emergency department visits and hospitalization in Omicron-infected cases were 3.89% and 0.96% respectively, significantly lower compared with 21.01% and 2.65% in the matched Delta cohort. Similar trends were observed for other pediatric age groups (5-11, 12-17 years) [26].

However, because of an enormous amount of infected cases due to the high transmissibility of the Omicron variant, infants and children aged 0-4 years during Omicron variant predominance beginning in late December 2021, U.S. were hospitalized at five times the number during the pre-Omicron period [27].

Risk Factors Associated with Severe COVID-19 in Children

In a review of 3106 hospitalized children by Woodruff et al. Risk factors for the severe disease were stratified by age group. For children < 2 years of age, risk factors were chronic lung disease, neurologic disorders, cardiovascular disease, prematurity, and airway abnormality. Among children 2-17 years, risk factors included feeding tube dependence, diabetes mellitus, and obesity. Additionally, infants < 1 year of age had the highest rates of hospitalization and severe COVID-19 compared to other age groups [28]. In other studies, diabetes, obesity, neurologic disorders, etc., but not asthma and immunocompromising conditions, were found to be associated with severe COVID-19 in children [29-32].

The Severe Spectrums of Omicron Variant Infection in Children

Multiple organ failures occurred in severe Covid-19 infected children. Duarte-neto and colleagues' study did autopsy with a minimally invasive method [33] in 5 Children died from COVID-19. Autopsy findings included mild to severe COVID-19 pneumonia, pulmonary micro-thrombosis, and cerebral edema with reactive gliosis, myocarditis, intestinal inflammation, and hemophagocytosis. SARS-CoV-2 was detected in all patients in the lungs, heart, kidney, and endothelial cells from the heart and brain in two patients with the multisystem inflammatory syndrome (MIS-C). Two major patterns of severe COVID-19 were observed: severe acute respiratory disease and diffuse alveolar damage, or MIS-C with the involvement of several organs. Besides the aforementioned severe spectrums in COVID-19 infected pediatric cases well demonstrated in other review

articles, here we mainly focused on seizure, croup, and MIS-C in the Omicron period.

Seizure

In a pre-Omicron period multinational study of neurological manifestations by Fink and colleagues, seizures were reported in 108 (8.5%) of 1278 children hospitalized with COVID-19 [34]. The study included patients from 30 centers across North and South America. In another study, seizures (20%) were the most frequent clinical diagnoses linked to hospitalization in Covid-infected children, followed by acute gastroenteritis, and respiratory tract infections (upper respiratory infection and bronchopneumonia) [35].

The announcement of the Japan Pediatric Society on March 15 showed that fevers and convulsions tended to increase in children infected with the omicron variant. The frequency of fevers was 80% during the omicron wave, but only about 40% in the early stages of the pandemic. The rate of febrile seizures at ages 1 to 4 stood at 9.4% during the omicron surging, but was 1.3% and 3% during the early stages of the COVID-19 outbreak and delta wave, respectively. The rate also increased for children aged 5 to 11 during the omicron wave [36].

In Ludvigsson's study, four children with COVID-19 Omicron variant infection were admitted with convulsions. However, the youngest and oldest children in the study fell outside the typical age range for febrile convulsions [37]. The finding was consistent with the South African paper [38]. This seems a random finding, but it could also demonstrate a different underlying mechanism behind the convulsions described in these reports, as opposed to traditional febrile seizures.

Croup

Croup (viral laryngotracheitis) is a common childhood upper respiratory disease, usually manifested with inspiratory stridor, hoarse voice, barking cough, and respiratory distress, complete airway obstruction in severe cases. The relatively smaller upper respiratory tract in children compared to adults has been thought to predispose them to more severe clinical presentations resembling croup. *Ex vivo* studies showed that the Omicron variant of SARS-CoV-2 replicates more rapidly in higher airways than previous variants, suggesting an increased risk for croup [39].

Indeed, Martinet et al analyzed 18 849 children hospitalized with SARS-CoV-2, 384 of whom (2.0%) had UAIs. Severe cases requiring mechanical ventilation, vasopressors, extracorporeal membrane oxygenation, or death occurred in 81 children (21%). SARS-CoV-2-infected UAI rates have increased, and the risk of croup has been higher with Omicron than with other variants [40]. Severe croup might result in a life-threatening condition [41].

Tunc et al [42] examined the data at his center confirming a sharp increase in cases of croup associated with the Omicron variant, nearly doubled compared to the rate in prior months. They also have appreciated a sharp rise in cases of croup seen in their pediatric emergency department. Croup patients during the Omicron surge were more likely to receive epinephrine, suggesting a more severe initial clinical presentation.

Brewster et al [43] performed a retrospective analysis of the incidence and clinical characteristics of croup associated with SARS-CoV-2 infection at a large freestanding children's hospital. Between 3/1/2020-1/15/2022, a total of 75 children were diagnosed with COVID-19-associated croup, 81% of whom presented during the Omicron period. Dexamethasone was administered to 97% of patients. Whereas 100% of hospitalized patients received epinephrine. Four patients required intensive care, with one escalating to continuous positive airway pressure. No patients required invasive ventilation or died.

MIS-C

MIS-C is a rare but severe complication of SARS-CoV-2 infection that mainly affects children. It is defined by WHO as an illness in a pediatric-aged patient (0 to 18 years) presenting with ≥ 3 days fever, elevated biomarkers of inflammation, and at least two clinical signs of multisystem involvement [44-47]. The clinical manifestations of patients with MIS-C vary in different age groups. Younger children aged 0 to 4 years, present a lower rate of severe symptoms and fewer admissions to the ICU, but more frequent conjunctival findings, skin rash, and abdominal pain [47,48]. Patients aged 18 to 20 years were more likely to have pneumonia, dyspnea, myocarditis, and cardiac dysfunction [44,47,48]. The onset of MIS-C follows peaks of SARS-CoV-2 infection, with an average of 4 weeks (range 2 to 5 weeks) [49]. Death usually results from myocardial dysfunction or/and shock.

Although MIS-C has clinical features in common with Kawasaki disease (KD), they are distinct entities [50-54]. Older children are typically affected by MIS-C (MIS-C, 5-14 years vs. KD, < 5 years). And MIS-C more commonly affects Afro-Caribbean, African descent, and Hispanic children, while KD by comparison is more prevalent in East Asian descent [54].

The trends over time of MIS-C were analyzed based on the prospective data from the NHS South Thames Pediatric Network (STPN). Compared with the Alpha wave; MIS-C rates per pediatric case were 95% lower during the Omicron period. 55 Of note, with the significant increase of pediatric cases in the Omicron period, the number of MIS-C cases was not increasing proportionally based on the data released on U.S CDC website [56].

Prevention of Severe COVID-19 Infected Pediatric Cases by Vaccine

After Omicron as the predominant variant of SARS-CoV-2, concerns about the effectiveness of current vaccines against the rapidly spreading omicron variant are increasing. Evidence demonstrated that vaccination remains effective in preventing a severe form of COVID-19 infection in children in the Omicron era. Dorabawila and colleagues' study demonstrated that the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11 years. However, vaccination of children 5-11 years was protective against severe disease [57]. In another study, Price et al. demonstrated that, during the omicron-predominant period, BNT162b2 vaccine effectiveness was 40% against hospitalization for Covid-19, 79% (95% CI, 51 to 91) against critical Covid-19 for adolescents 12 to 18 years of age, while vaccine effectiveness against hospitalization among children 5 to 11 years of age was 68%, 58.

Conclusion

SARS-CoV-2 Omicron variant with so far the highest transmissible capability is causing the current global pandemics. The omicron variant could significantly increase the risk of re-infection and vaccine breakthrough infections, as it possesses key mutations in the spike protein that affect neutralizing antibody response induced by prior infection or vaccination. Even though Omicron infected pediatric cases were less severe than previous variant-infected cases, however, because of an enormous amount of infected cases due to the high transmissibility, infants and children during Omicron variant predominance were hospitalized at a higher number during the Omicron period. The severe spectrums of Omicron infected pediatric cases were slightly different from those in the pre-Omicron period. Seizure and croup were two significant severe spectrums, more occurred in Omicron-infected pediatric cases, while MIS-C was less frequent. Vaccination is strongly recommended for eligible children for preventing hospitalization and critical Covid-19 cases.

Author Contributions

Jianguo Zhou looked up the literature and wrote the first manuscript. Wenhao Zhou and Guoping Lu revised the manuscript. All authors reviewed and agreed on the final manuscript.

Funding

This study was funded by the National Key Research and Development Program of China (2021YFC2701800, 2021YFC2701801) and the Shanghai Municipal Science and Technology Major Project (ZD2021CY001).

Compliance with Ethical Standards

Ethical approval not needed.

Conflict of Interest: the authors have no conflict of interest to disclose. No financial benefits have been received.

References

1. Ladhani SN, Amin-Chowdhury Z, Davies HG, Aiano F, Hayden I, Lacy J, et al. COVID-19 in children: analysis of the first pandemic peak in England. *Archives of Disease in Childhood*. 2020; 105(12): 1180-1185. doi:10.1136/archdischild-2020-320042.
2. Nikolopoulou GB, Maltezou HC. COVID-19 in Children: Where do we Stand?. *Archives of Medical Research*. 2021; 53(1): 1-8. doi:10.1016/j.arcmed.2021.07.002.
3. Alsouhime F, Temsah M, Al-Nemri AM, Somily AM, Al-Subaie S. COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome. *Journal of Infection and Public Health*. 2020; 13(12): 1791-1796. doi:10.1016/j.jiph.2020.10.008.
4. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet. Infectious Diseases*. 2020; 20(8): 911-919. doi:10.1016/S1473-3099(20)30287-5.
5. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. *Lancet (London, England)*. 2021; 398(10317): 2126-2128. doi:10.1016/S0140-6736(21)02758-6.
6. Kannan S, Ali PSS, Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. *European review for medical and pharmacological sciences*. 2021; 25(24): 8019-8022. doi:10.26355/eurev_202112_27653.
7. Dong Y, Mo X, Hu Y, Qi X, Jiang F, et al. Epidemiology of COVID-19 Among

- Children in China. *Pediatrics*. 2020; 145(6): e20200702.
8. LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, et al. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. *JAMA neurology*. 2021; 78(5): 536. doi:10.1001/jamaneurol.2021.0504
 9. Grabowski F, Kocharczyk M, Lipniacki T. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0–3.3 Days Can Be Explained by Immune Evasion. *Viruses*. 2022; 14(2): 294. doi:10.3390/v14020294.
 10. Ferguson N, Ghani A, Cori A, Hogan A, Hinsley W, Volz E. Report 49: Growth, population distribution and immune escape of Omicron in England. Imperial College London (16-12-2021). doi: <https://doi.org/10.25561/2021>; 93038.
 11. Vogel G, Kupferschmidt K. Early lab studies shed light on Omicron's behavior. *Science*. 2021; 374(6575): 1543-1544. doi:10.1126/science.acz9878.
 12. Murchu EO, Byrne P, Carty PG, Gascun CD, Keogan M, O'Neill M, et al. Quantifying the risk of SARS-CoV-2 reinfection over time. *Reviews in Medical Virology*. 2021; 32(1). doi:10.1002/rmv.2260.
 13. Nicole Wolter, Waasila Jassat, Sibongile Walaza, Richard Welch, Harry Moultrie, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. *Medrxiv*. 2021; <https://doi.org/10.1101/2021.12.21.21268116>.
 14. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature*. 2022; 602(7898): 664-670.
 15. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet (London, England)*. 2021; 399(10321): 234-236. doi:10.1016/S0140-6736(21)02844-0.
 16. Clemens SAC, Weckx L, Clemens R, Mendes AVA, Souza AR, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet (London, England)*. 2022; 399(10324): 521-529. doi:10.1016/S0140-6736(22)00094-0.
 17. Ferguson N GA, Hinsley W, Volz E. Hospitalisation risk for Omicron cases in England. <https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf>. Published 2021. Accessed 2021.
 18. Collie S, Champion J, Moultrie H, Bekker L, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. *The New England Journal of Medicine*. 2021; 386(5): 494-496. doi:10.1056/NEJMc2119270.
 19. Badal S, Bajgain KT, Badal S, Thapa R, Bajgain BB, Santana MJ. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: A systematic review and meta-analysis. *Journal of Clinical Virology*. 2020; 135: 104715. doi:10.1016/j.jcv.2020.104715.
 20. Steinman JB, Lum FM, Ho PP, Kaminski N, Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. *Proceedings of the National Academy of Sciences of the United States of America*. 2020; 117(40): 24620-24626. doi:10.1073/pnas.2012358117.
 21. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proceedings of the Royal Society B: Biological Sciences*. 2015; 282(1821): 20143085. doi:10.1098/rspb.2014.3085.
 22. Wald ER, Schmit KM, Gusland DY. A Pediatric Infectious Disease Perspective on COVID-19. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2020; 72(9): 1660-1666. doi:10.1093/cid/ciaa1095.
 23. Chang T, Wu J, Chang L. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. *Journal of the Formosan Medical Association*. 2020; 119(5): 982-989. doi:10.1016/j.jfma.2020.04.007.
 24. Shekerdeman LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA pediatrics*. 2020; 174(9): 868. doi:10.1001/jamapediatrics.2020.1948.
 25. Wu H, Zhu H, Yuan C, Yao C, Luo W, Shen X, et al. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Network Open*. 2020; 3(6): e2010895. doi:10.1001/jamanetworkopen.2020.10895.
 26. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. *medRxiv*. 2022. doi:10.1101/2021.12.30.21268495.
 27. Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, et al. Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022. *Morbidity and Mortality Weekly Report*. 2022; 71(11): 429-436. doi:10.15585/mmwr.mm7111e2.
 28. Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk Factors for Severe COVID-19 in Children. *Pediatrics*. 2021; 149(1). doi:10.1542/peds.2021-053418.
 29. Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk Factors for Severe COVID-19 in Children. *Pediatrics*. 2021; 149(1). doi:10.1542/peds.2021-053418.
 30. Havers F, Fry AM, Chen J, Christensen D, Moore C, Peacock G, et al. Hospitalizations Attributable to Respiratory Infections among Children with Neurologic Disorders. *The Journal of pediatrics*. 2016; 170: 135-141.e5. doi:10.1016/j.jpeds.2015.11.030.
 31. Prata-Barbosa A, Lima-Setta F, Santos GRD, Lanzotti VS, Castro REVD, Souza DCD, et al. Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study. *Jornal De Pediatria*. 2020; 96(5): 582-592. doi:10.1016/j.jped.2020.07.002.
 32. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. *JAMA pediatrics*. 2020; 174(10): e202430. doi:10.1001/jamapediatrics.2020.2430.
 33. Duarte-Neto AN, Caldini EG, Gomes-Gouvêa MS, Kanamura CT, Monteiro RADA, Ferranti JF, et al. An autopsy study of the spectrum of severe COVID-19 in children: From SARS to different phenotypes of MIS-C. *EClinicalMedicine*. 2021; 35: 100850. doi:10.1016/j.eclinm.2021.100850.
 34. Fink EL, Robertson CL, Wainwright MS, Roa JD, Lovett ME, Stulce C, et al. Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C. *Pediatric Neurology*. 2021; 128: 33-44. doi:10.1016/j.pediatrneurol.2021.12.010.
 35. Cloete J, Kruger A, Masha M, Plessis NMD, Mawela D, Tshukudu M, et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. *The Lancet. Child & Adolescent Health*. 2022; 6(5): 294-302. doi:10.1016/S2352-4642(22)00027-X.
 36. Japan M. Fevers, convulsions seen more in children during omicron wave: Japan Pediatric Society. <https://mainichi.jp/english/articles/20220316/p2a/00m/0na/006000c>. Accessed May 11st, 2022.
 37. Ludvigsson JF. Convulsions in children with COVID-19 during the Omicron wave. *Acta paediatrica*. 2022; 111(5): 1023-1026. doi:10.1111/apa.16276.
 38. Cloete J, Kruger A, Masha M, Plessis N M du, Mawela D, et al. Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa. *medRxiv*. 2021. <https://doi.org/10.1101/2021.12.21.21268108>.
 39. Hui KPY, Ho JCW, Cheung M, Ng K, Ching RHH, Lai K, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature*. 2022; 603(7902): 715-720. doi:10.1038/s41586-022-04479-6.
 40. Martin B, DeWitt PE, Russell S, Sanchez-Pinto LN, Haendel MA, et al. Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2-A Report From the US National COVID Cohort Collaborative. *JAMA Pediatr*. 2022; e221110.

41. Murata Y, Tomari K, Matsuoka T. Children With Croup and SARS-CoV-2 Infection During the Large Outbreak of Omicron. *The Pediatric infectious disease journal*. 2022; 41(5): e249-e249. doi:10.1097/INF.0000000000003484.
42. Tunç EM, Shin CKJ, Usoro E, Migita R T, Trehan I, et al. Pediatric Croup during the COVID-19 Omicron Variant Surge. *medRxiv*. 2022; <https://doi.org/10.1101/2022.02.02.22270222>.
43. Brewster RCL, Parsons C, Laird-Gion J, Hilker S, Irwin M, Sommerschild A, et al. COVID-19-Associated Croup in Children. *Pediatrics*. 2022; doi:10.1542/peds.2022-056492.
44. Hoste L, Paemel RV, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. *European Journal of Pediatrics*. 2021;180(7):2019-2034. doi:10.1007/s00431-021-03993-5.
45. Tang Y, Li W, Baskota M, Zhou Q, Fu Z, Luo Z, et al. Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: a systematic review of published case studies. *Translational pediatrics*. 2021;10(1):121-135. doi:10.21037/TP-20-188.
46. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic. *JAMA pediatrics*. 2021;. doi:10.1001/jamapediatrics.2021.0630
47. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. *Pediatric Infectious Disease Journal*. 2020;39(11):e340-e346. doi:10.1097/INF.0000000000002888.
48. Abrams JY, Godfred-Cato SE, Oster ME, Chow EJ, Koumans EH, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. *The Journal of pediatrics*. 2020; 226: 45-54. e41.
49. Dionne A, Son MBF, Randolph AG. An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. *The Pediatric Infectious Disease Journal*. 2022;41(1):e6-e9. doi:10.1097/INF.0000000000003393.
50. Bukulmez H. Current Understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and Its Distinction from Kawasaki Disease. *Current Rheumatology Reports*. 2021;23(8). doi:10.1007/s11926-021-01028-4.
51. Algarni AS, Alamri NM, Khayat NZ, Alabdali RA, Alsubhi RS, Alghamdi SH. Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. *World Journal of Pediatrics*. 2022;18(2):83-90. doi:10.1007/s12519-021-00499-w.
52. Suksatan W, Chupradit S, Yumashev AV, Ravali S, Shalaby MN, Mustafa YF, et al. Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells. *International Immunopharmacology*. 2021;101:108217. doi:10.1016/j.intimp.2021.108217
53. Wu EY, Campbell MJ. Cardiac Manifestations of Multisystem Inflammatory Syndrome in Children (MIS-C) Following COVID-19. *Current Cardiology Reports*. 2021;23(11). doi:10.1007/s11886-021-01602-3.
54. Farooq A, Alam F, Saeed A, Butt F, Khaliq MA, Malik A, et al. Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) under the Setting of COVID-19: A Review of Clinical Presentation, Workup and Management. *Infectious Diseases*. 2021;14:117863372110266. doi:10.1177/11786337211026642.
55. Cohen JM, Carter MJ, Cheung CR, Ladhani S, Group EP-TS. Lower Risk of Multisystem Inflammatory Syndrome in Children (MIS-C) with the Delta and Omicron variants of SARS-CoV-2. *medRxiv*. 2022; <https://doi.org/10.1101/2022.03.13.22272267>.
56. CDC. Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States. Published 2022. Accessed May 11st, 2022.
57. Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant. *medRxiv*. 2022; <https://doi.org/10.1101/2022.02.25.22271454>.
58. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. *The New England journal of medicine*. 2022;. doi:10.1056/NEJMoa2202826.